
Teva Reports Positive Phase 3 Results for AJOVY in Preventing Migraines in Youth
Teva Pharmaceutical Industries has announced encouraging results from its Phase 3 SPACE study, which evaluated the efficacy and safety of AJOVY (fremanezumab) for preventing episodic migraines in children and adolescents aged 6 to 17 years. The study demonstrated a statistically…